PhD Scientific Days 2025

Poster Session II. - E: Pathological and Oncological Sciences

Prognostic Impact of a Senescence Gene Signature in Multiple Myeloma

Name of the presenter

Lehoczki Andrea

Institute/workplace of the presenter

Institute of Preventive Medicine and Public Health

Authors

Andrea Lehoczki¹, Otilia Menyhárt², Csaba Kiss², Balázs Győrffy²

1: Institute of Preventive Medicine and Public Health
2: Dept. of Bioinformatics

Text of the abstract

Introduction: Multiple myeloma (MM), an incurable malignancy of plasma cells, is predominantly an age-related disease, with the majority of cases occurring in patients over the age of 60. Cellular senescence, a fundamental biological process underlying aging, has been increasingly recognized for its critical role in developing age-related malignancies. Aims: In this study, we aimed to investigate the prognostic significance of genes implicated in the molecular mechanisms of senescence within a large cohort of MM patients. Methods: Gene expression and clinical data from 1,416 MM patients were obtained from four GEO datasets and integrated into a unified database. The raw data were processed using MAS5 normalization, scaling adjustments, and JetSet probe selection to ensure cross-platform comparability. A curated set of senescence-associated genes, the SenMayo gene signature, was employed for subsequent analyses. The final gene signature was computed as a weighted mean expression of 122 senescence-associated genes, with weights derived from univariate hazard ratios. Prognostic significance was evaluated using Cox regression, Kaplan-Meier survival analysis, and multivariate models incorporating clinical parameters such as gender, isotype, and molecular subtypes. False Discovery Rate (FDR) correction was applied to ensure the statistical robustness of findings. Results: The weighted SenMayo gene signature strongly correlated with overall survival in MM patients (HR = 0.6, 95% CI = 0.47–0.76, p = 1.7e-05). The 75th percent probability of survival was reached at 36.1 months in the low-expression patient group, compared to 57 months in the high-expression group. Independent validation in datasets with sufficient patient numbers confirmed the prognostic value of the SenMayo signature. Multivariate analyses further established the SenMayo signature as an independent prognostic factor, even when accounting for established clinical parameters such as sex and isotype. Conclusions: Our findings underscore the robustness and independence of the SenMayo gene signature as a predictor of overall survival in multiple myeloma. This signature provides clinically valuable insights into the role of cellular senescence in disease progression. Funding: EKÖP-2024-9